Bio-Rad Laboratories (BIO) Set to Post Quarterly Earnings on Wednesday

Bio-Rad Laboratories (NYSE:BIO) is projected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Bio-Rad Laboratories to announce earnings of $2.23 per share and revenue of $649.94 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $2.62 EPS for the quarter, topping analysts’ consensus estimates of $1.75 by $0.87. The firm had revenue of $651.00 million during the quarter, compared to analyst estimates of $623.99 million. The business’s quarterly revenue was down .1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.61 EPS. On average, analysts expect Bio-Rad Laboratories to post $9.28 EPS for the current fiscal year and $8.89 EPS for the next fiscal year.

Bio-Rad Laboratories Price Performance

NYSE:BIO opened at $380.58 on Wednesday. The firm has a 50-day moving average of $374.06 and a two-hundred day moving average of $313.22. The stock has a market cap of $10.18 billion, a P/E ratio of 46.13 and a beta of 1.07. Bio-Rad Laboratories has a 1-year low of $236.73 and a 1-year high of $396.23.

Analyst Ratings Changes

Several research analysts recently commented on the company. Wells Fargo & Company boosted their price target on Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada raised their price objective on Bio-Rad Laboratories from $320.00 to $370.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Citigroup raised their price objective on Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings raised Bio-Rad Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Bio-Rad Laboratories presently has a consensus rating of “Hold” and an average target price of $343.33.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures and markets products and systems used in life science research and clinical diagnostics. Its life science portfolio includes laboratory instruments, reagents, software and consumables used in areas such as genomics, proteomics, cell biology, biopharmaceutical development and quality control.

The company’s clinical diagnostics business provides systems, reagents and software for blood typing, infectious disease testing, diabetes monitoring, quality control and other diagnostic applications.